PDD Holdings on Track for Highest Close Since March 2021 — Data Talk
PDD Holdings Inc. Sponsored ADR Class A (PDD) is currently at $158.11, up $4.48 or 2.92%
--Would be highest close since March 16, 2021, when it closed at $160.89
--Currently up seven of the past eight days
--Currently up three consecutive days; up 8.7% over this period
--Best three day stretch since the three days ending May 6, 2024, when it rose 11.37%
--Up 26.31% month-to-date; on pace for best month since Nov. 2023, when it rose 45.38%
--Up 8.07% year-to-date
--Down 22.04% from its all-time closing high of $202.82 on Feb. 17, 2021
--Up 121.38% from 52 weeks ago (May 26, 2023), when it closed at $71.42
--Would be a new 52-week closing high
--Up 142.05% from its 52-week closing low of $65.32 on May 31, 2023
--Traded as high as $164.69; highest intraday level since March 16, 2021, when it hit $169.45
--Up 7.2% at today's intraday high
--Seventh best performer in the Nasdaq 100 today
--Sixth most active stock in the Nasdaq 100 today
All data as of 12:51:35 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
May 24, 2024 13:08 ET (17:08 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks